Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition
Chemotherapy-caused negative effects restrain anti-tumor efficiency, with hyperlipidemia being the most typical associated disease to result in treatment failure. Within this work, a chimeric peptide-engineered nanomedicine (designated as PRS) was fabricated for that synergistic suppression of tumor growth and therapy-caused hyperlipidemia. In this particular nanomedicine, the tumor matrix-targeting peptide palmitic-K(palmitic)CREKA can self-assemble right into a nano-micelle to encapsulate Rapamycin (mTOR inhibitor) and SBC-115076 (PCSK9 inhibitor). This PRS nanomedicine exhibits a uniform nano-distribution with higher stability which boosts intracellular drug delivery and tumor-targeting delivery. Also, PRS was discovered to synergistically hinder tumor cell proliferation by interrupting the mTOR path and reducing Rapamycin-caused hyperlipidemia by growing producing LDLR. In vitro as well as in vivo results demonstrate the brilliance of PRS for systematic suppression of tumor growth and also the decrease in hyperlipidemia without initiating every other toxic negative effects. The work proposes a classy technique to hinder tumor growth as well as provides new insights for cooperative control over chemotherapy-caused negative effects.